A PRACTICAL MODEL FOR EARLY IDENTIFICATION OF PROSPECTIVE HIGH

NEED HIGH COST PATIENTS

Avivit Golan Cohen ^{1,2} MD, Shlomo Vinker ^{1,2} MD, Adi Isaacson MD, Eva Avramovich ^{1,3} MD

MPH, Eugene Merzon ^{1, 2} MD

Leumit Health Services, Tel-Aviv, Israel;

Department of Family Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel

Aviv, Israel;

Department of Management, Bar-Ilan University, Israel

Corresponding author: <u>Dr. Avivit Golan-Cohen</u>, 23 Shprinzak St., Tel Aviv, Israel, tel. 972-50-

6990363, fax 972-3-6949624. E-mail- agolanchoen@leumit.co.il

Ethics approval: The study protocol was approved by the Shamir Medical Center Review Board

and the Research Committee of LHS (ID number 0235-18-ASAF, Date: 9.10.2018)

Consent for publication: Not applicable

Availability of data and materials: The datasets analyzed during the current study are not publicly

available because it is a business Information, but are available from the corresponding author on

reasonable request.

Competing interests: The authors declare that they have no competing interests.

Funding: The authors declare that there was no funding in this research

Acknowledgments: authors would like to express their deep and sincere gratitude to Mr. Haim

Fernandes, Mr. Ilia Merhasin, and Mrs. Etty Cohen-Adar.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Authors' contribution:

AVG: contributing the research questions and study design, literature search, data collection,

analysis and interpretation, writing the manuscript.

SV: contributing the research questions and study design, drafting the manuscript, analysis and

interpretation.

AI: literature search, data analysis and interpretation, writing the manuscript.

EA: data interpretation, editing the manuscript.

EM: contributing the research questions and study design, data collection, analysis and

2

interpretation, drafting the manuscript.

Word Count: 2713

Abstract word count: 191

ABSTRACT 1 **Background:** High Need-High Cost (HNHC) patients are those who experience poor health 2 outcomes and high health care costs. Early identification may improve outcomes and lower costs. 3 **Aim:** Development of a model using retrospective data to identify patients at risk for becoming 4 HNHC patients, in order to efficaciously plan interventions. 5 Methods: Data from a large Israeli Health Maintenance Organization (HMO) that includes 6 488,615 clients above the age of 21 were examined. Multivariate linear regression models were 7 developed using 2012–2016 health expenditure as a dependent variable. 8 **Results**: The number of yearly purchases of medications for chronic disorders, yearly outpatient 9 visits, yearly emergency department and hospital admissions and the last measured HgA1c level 10 were highly predictive of increased expenditure over a five-year period. Each of these indicators 11 has a different coefficient of influence. 12 **Conclusions:** We developed a predictive model, based on easily obtained data from electronic 13 medical records that enabled us to identify a population at risk for becoming HNHC in the next 14 five years, a time window allows for intervention. Further research is needed to evaluate whether 15 this is an early enough stage to implement pro-active intervention in the primary care setting. 16 Trial registration: retrospectively registered. **Keywords:** complex patients, High Need-High Cost, Electronic Medical Records (EMR), 17 medical costs prediction 18 19

HIGHLIGHTS: 21 In this study, we developed a numerical point system calculator, to indicate a risk score for health 22 deterioration within 5 years of patients, by using numerical indicators existing in standard EMR 23 data. 24 The indicators introduced into this calculated risk can guide healthcare providers to the needed 25 areas of intervention. The display of indicators also promotes optimization of care management 26 and continuity of care. 27 This risk score is expected to focus the attention of primary care teams on the population that will 28 benefit most from it, as well as to evaluate the effectiveness of specific interventions. 29

INTRODUCTION: 31 Coping with the rising prevalence of chronic diseases is one of the major challenges facing 32 health-care systems throughout the world. The increase in both, longevity and disease 33 complexity, has led to a growing number of patients with multiple concurrent morbidities; 34 ranging from 50% to 98% of people older than 65 years in various studies [1-2]. These co-35 morbidities have complex interactions that can influence the progression and management of 36 both disorders [1]. From the economic point of view, complex co-morbidities translate to tripling 37 the national expenditure on health per capita, and it is expected to continue to rise [2]. The 38 increasing burden on resources is compelling healthcare systems to seek ways to ease the burden. 39 Analyses of health expenditures worldwide reveals a pattern; approximately 5% of the 40 population incurs roughly 50% of all national health care costs [3-5]. Therefore, in an attempt to 41 stem the tide of rising costs, the focus has been on this 5% of the population. It was assumed that 42 a comprehensive approach would reduce multi-morbidity impact, thus resulting in reduced 43 expenditure [6]. 44 Effective management requires a practical algorithm to identify which patients are more likely to 45 deteriorate and to generate substantial future health expenditures. Identification of "complex 46 patients" would be effective and can lead to reduced health care costs only if it occurs in a timely 47 manner. The treatment plan can then be adjusted to impact the course of illness [4]. Originally, 48 researchers focused on patients with specific single diseases known to have major health 49 repercussions (such as CHF or diabetes) or patients with multi-morbidity [1, 4]. Many studies 50 have been conducted on modeling healthcare costs data as an estimator of medical complexity 51 [7-10]. However, when the identified patients presented medically complex conditions, the 52

53

ability to predict who would deteriorate and become HNHC was limited [11-12].

In 1987, the Charlson Comorbidity Index was developed to predict the risk of death within a year 54 of hospitalization based on the number of chronic diseases [7]. Charlson et al. used 19 categories 55 of diseases, each with a score of 1 to 6. Higher overall calculated score led to a greater chance of 56 dying in the following year. Over the years, the index underwent modifications and in 2008 was 57 validated and adjusted so that it could predict a future increase in medical expenditure [8]. 58 Several additional models have been developed (chronic illness and disability payment system 59 [CDPS], diagnostic cost groups [DCGs], RxGroups, episode risk groups [ERGs]) [10] are among 60 the most quoted. These models use medical insurance claims to generate the main predictor 61 variables [9]. Some of these models predict patient's chances of dying, some the odds of 62 hospitalization and others predict future total healthcare costs. It turns out that not all patients 63 with multiple chronic diseases deteriorate in a manner that would increase their medical 64 expenditures. Complexity measured only by a quantitative count of chronic diseases does not 65 produce an accurate and useful prediction of the individual patient that may benefit from a 66 proactive intervention [5]. 67 In recent years, the Commonwealth Fund and others have brought to the forefront the role of 68 functional and psychosocial difficulties associated with significant risk factors for future health 69 deterioration [1, 3-5, 11-12]. They found that patients with three or more chronic diseases are 70 more likely to deteriorate if they have functional limitations, poor disease self-management, 71 economic problems, or lack a support system, resulting in fragmentation and poor coordination 72 of care [13-14] and increased pressure on primary care professionals (PCPs) [14]. Following 73 these new insights, the terminology pertaining to the 5% of the population that incurs 50% of 74 health expenditure has been changed to "High Need High Cost" (HNHC) patients. The term 75 reflects the understanding that the management of all complex patient needs, including those 76 beyond the medical disorders, is responsible for the high cost. 77 An effective definition of the intervention group [18-19] needs to identify not only the patients at 78 risk of deterioration, but within this group, those who would benefit from the intervention. 79 Therefore, the indicators chosen should reflect not only a patient's current state, but through 80 continuous monitoring, they should also reflect any future changes incurred through 81 interventions. Monitoring enables evaluation of the effectiveness of the intervention, and can 82 potentially motivate both the staff and the patients. 83 Of the published accepted characteristics of HNHC, we chose indicators associated with high 84 health expenditures such as - clinical parameters (e.g. certain diseases or treatments or lab results 85 that indicate an unbalanced disease state), health resources utilization (e.g. multiple inpatient 86 hospitalizations or multiple physician visits) or patient's executive functioning (e.g. compliance 87 to medication use or to follow-up visits of physician) [10]. 88 We excluded indicators that did not meet the SMART model (Specific, Measurable, 89 Attainable/Achievable, Realistic/Relevant, and Time-Bound) [20] which is the most common 90 model for the examination of the compatibility of selected indicators. According to the SMART 91 model, indicators should be: 92 1. Specific – accurately describe the value we want to measure. 93 2. Measurable – return the same value every time it is measured under the same conditions. 94 3. Attainable – easy to extract from existing data. 95 4. Relevant – directly connected to the desired intervention and influenced by it. 96 5. Time-bound – changes can be tracked over a period of time. 97 Exclusion of indicators that cannot be influenced or changed is important because their inclusion 98 would skew the results and create a score that is not sensitive to changes. A good example of this 99 is age - an eminent risk factor for deterioration that would mask improvements in any other 100 indicator. 101 The objective of our study was to formulate a predictive model based on the selected simple 102 numerical indicators from the electronic medical records (EMRs), which would allow us to 103 identify a population at risk for becoming HNHC, at a stage with potential for pro-active 104 intervention in the primary care setting. 105 **METHODS:** 106 Leumit Health Services (LHS) is an HMO in Israel serving about 720,000 members. LHS has a 107 comprehensive computerized database continuously updated with patients' demographics, 108 medical encounters, laboratory tests and medication prescriptions, and healthcare services 109 utilization. 110 Study period and population: 111 **Study period:** our study was conducted retrospectively on records from 2011 until 2016. 112 **Study population** consisted of all LHS members over the age of 21 at the time of the study 113 period - 488,615 patients. 114 **Exclusion criteria:** patients who, at the beginning of the study, were diagnosed with cancer, 115 patients requiring dialysis, and patients with diseases defined by the Israeli Ministry of Health as 116 "costly" and covered with a special budget – Thalassemia major, Gaucher, Hemophilia and 117 AIDS. 118 Patients who died or left the HMO during the study period were also excluded. 119 After these exclusions, the data of 460,912 patients was analyzed. 120 Total expenditures for 2011 for each patient served as the baseline against which the change in 121 expenditure was measured during the evaluation period. Total medical costs were calculated for 122 each patient for each year from 2012 to 2016, including: medications, hospital admissions, 123 emergency department (ED) visits, office-based physician visits (primary care and consultants), 124 hospital outpatient visits, ambulatory medical services (laboratory and imaging procedures, 125 physical and occupational therapy, ambulances, etc.) and medical devices (such as insulin pumps 126 and supplies, glucometers, orthopedic assistance devices, etc.). These were obtained directly 127 from the billing database of LHS. 128 Data regarding chronic medication consumption was drawn from the LHS pharmacy claims, 129 based on the Anatomical Therapeutic Chemical (ATC) classification system. A medication was 130 considered chronic if the patient purchased at least 3 prescriptions during the 180 days preceding 131 the index date. 132 The number of hospital admissions and ER visits was calculated according to hospital claims. 133 Data on visits to primary care physicians and community consultants were obtained from the 134 LHS EMR. Only face to face visits in an LHS ambulatory setting were included. 135 Uncontrolled diabetes mellitus (DM) was defined according to the last measured HgA1c level 136 result (above 8%) in 2011 and reflected poor glycemic control. 137 Multivariate linear regression models were created using the following formula on the 2012– 138 2016 data and the stepwise approach to locate the most influential variables. In order to improve 139 the statistical test, a deviation of at least 5 standard deviations was filtered out. 140 $Y_{Total\ Medical\ Costs} = \alpha + \beta_1 X_{1t} + \beta_2 X_{2t} + \beta_3 X_{3t} \dots + \beta_n X_{nt} + u_t$ 141 Y- is the dependent (explained) variable. 142 α – is the constant alpha. In our case it reflects the "minimum" average expenditure given the 143 other variables. 144 X_n – are the independent (explanatory) variables $X_1, X_2, X_3 \dots X_n$ 145 β – is the coefficient for each independent (explanatory) variable β_1 , β_2 , β_3 ,.. etc 146 u - is a random interference, the part that is not explained by the model. 147 Regression analysis calculated all independent (X) variables in the analysis as numerical. 148 Additionally, we used dummy variables and when the coefficient changed mid-regression (e.g. 149 for HgA1C), we utilized the piecewise approach. 150 The *p-value* of each variable and the adjusted *R-squared* values were used to test all possible 151 linear regression models to predict total medical costs in combination with the other available 152 independent variables. **R-squared** is the proportion of variability in a data set that provides a 153 measure of how well the future outcome variable (total medical costs) is likely to be predicted by 154 the independent continuous, ordinary and dummy variables in our model. The Kolmogorov-155 Smirnov test was used for the goodness of fit test. Assumptions were two sided with an α of 0.05. 156 Statistical analysis was performed using STATA 12.0. 157 The study had no external funding source. 158 **RESULTS:** 159 Baseline study population characteristics are presented in **Table 1**. As expected, age was a 160 remarkable predictor for future cost, both as a categorical (Table 2) and as a continuous (Table 161 3) variable. Although age was highly correlated with future health expenditure we decided to 162 exclude it from the model. After exclusion of age R squared remained almost the same. After 163 inclusion age as a categorical and not a continuous variable the result didn't changed. 164 In Table 3 we described correlation between the dependent variable and other variables selected 165 into the regression model, in order to build the final score. Variables for which correlation was 166 not statistically significant (gender, mean last creatinine, mean last hemoglobin level) or the 167 association with future medical cost was obvious (e.g. age) were not included in the model. The 168 number of hospital admissions per year and the number of hospitalization days per year showed 169

co-linearity and contributed to cost prediction in a similar and significant manner. We decided to 170 use only the *number* of hospital admissions per year because this indicator better reflects the 171 dynamics of the patients and the intervention necessary for their care. 172 Blood glycosylated hemoglobin (HgA1c) level was found to be a strong indicator of future costs, 173 even when its results were in the normal range (less than 5.5%). 174 After the first regression model (**Table 4**) identified the most significant variables, we 175 incorporated dummy variables in our second regression model (Table 5), to achieve better 176 prediction for a future medical cost model. 177 In our dataset, 5,900 patients had uncontrolled diabetes mellitus (DM), according to their last 178 measured HgA1c (>8%). We hypothesized and examined whether there was an independent and 179 statistically significant synergistic relationship in the *combination* of uncontrolled DM with the 180 other indicators using dummy variables. We found the association to be statistically significant 181 with emergency department (ED) visits (1173 patients), hospitalizations (851 patients) and 182 having less than 4 chronic medications (2164 patients), but not for outpatient visits (**Table 6**). To 183 reflect this in our final score, a "penalty" was set for the relevant variables. 184 The final predictive model was formulated using the following indicators: 185 - The mean number of chronic disease medications purchased per year. This was the most 186 significant indicator. Due to a low number of patients (270), those receiving 16 medications or 187 higher were grouped together. 188 - The mean number of outpatient visits per year. Up to 30 visits per year showed good 189 correlation. 30-50 visits per year were still significant, but each additional visit had less influence 190 on overall future costs. More than 50 visits per year (1300) were excluded from the final 191 calculation. 192 - The mean number of ED admissions per year. The first visit was the most significant. 193 - The mean number of hospital admissions per year. Up to 3 visits a year showed very significant 194 financial correlation. More than 4 visits failed to increase the risk and were therefore grouped 195 with 3 visits per year. 196 - The last measured HgA1c level. 197 - The aforementioned "penalties" for uncontrolled DM concurrent with other variables. 198 199 **DISCUSSION:** Leading global health organizations invest considerable resources in defining the requirements 200 for pro-active intervention programs aimed at reducing healthcare expenditure by slowing or 201 stopping the deterioration of patients at risk of becoming High Need-High Cost [22-23]. Such 202 intervention plans require the timely identification of the appropriate target patient population. 203 Whereas health care systems currently tend to rely on the intuitive detection of "complex 204 patients" by family physicians (qualitative detection) [18, 23] or the use of computerized 205 detection based solely on the number of chronic diseases (quantitative detection) [24-25], these 206 methods have proven ineffective, and allow many of those in need to go unnoticed while 207 including patients that will stay stable for many years. 208 There is a noticeable increase in the use of predictive models, using linear regression techniques, 209 to estimate the expected total health care costs for managed care organizations. Various data 210 sources have been used for such predictive modeling, including medical and pharmaceutical 211 insurance claims, health risk-assessment surveys, and laboratory data [26-28]. The computerized 212 predictive models can be used for proactive identification of high-risk patients for the effective 213 adaptation of disease management programs [28-31]. 214 In this study, we developed a predictive model, which is based on numerical indicators with the 215 most significant association with patient medical expenditure within 5 years, as an expression of 216 health deterioration during this time period. We hypothesize that this model will enable us to 217 detect a population at risk for deterioration, with a sufficient time period for effective pro-active 218 intervention in primary care. 219 The next goal will be to develop a weighted numerical risk score, based on the relative influence 220 of the variables, included in our predictive model. 221 A numerical point system awarded to each of these variables, according to its appropriate risk 222 value, will be calculated into a final predictive score between 0-100. A higher score will indicate 223 a higher risk for health deterioration within 5 years. 224 This calculated risk score will enable us to build a mechanism for the efficient identification of 225 complex patients, and to put additional focus on their management in an attempt to prevent 226 deterioration to HNHC, as well as to evaluate the effectiveness of specific interventions. 227 The indicators introduced into this calculated risk will guide healthcare providers to the needed 228 areas of intervention. The display of indicators also promotes optimization of care management 229 and continuity of care. 230 The introduction of this calculated risk score for deterioration is expected to focus the attention 231 of primary care teams on the population that will benefit most from it. It is important to 232 continually evaluate each intervention while receiving feedback from family physicians who are 233 familiar with their "complex" patients, know patients' ability to manage their illness and the 234 factors which affect their disease control. Such feedback is very important because effective 235 involvement of the primary care team is critical for the success of the intervention [18-19]. 236 Strengths and weaknesses: 237

The main strengths of the study are its large size, and its real-world, population-based nature. An 238 additional strength is the inclusion of a multitude of numerical variables that could be identified 239 in most health care organizations. 240 However, there are some weaknesses, including its retrospective design. Furthermore, relevant 241 clinical variables such as the specific diagnosis of a chronic illness (both somatic and psychiatric) 242 and the severity of its presentation were not included in the model because this data was not 243 accurately presented in the medical records. 244 In conclusion, we formulated a predictive model for precise and early identification of patients 245 whose prognosis may be altered before they experience medical deterioration, by using 246 numerical indicators existing in standard EMR data. Using this model may benefit the population 247 that will potentially improve considerably following an intervention program. 248 The next step should be to integrate a calculated risk score for health deterioration into the LHS 249 EMR and to prospectively evaluate its contribution towards reducing the utilization of health care 250 resources and possible deterioration of patients to HNHC. 251 252

Table 1. Population characteristics at baseline, 2011

Number of patients		Number 431413 patients (Mean; %)
Male Gender		219589 (50.9%)
Mean Age(years)		43.94± 16
Number of Chronic Medications (N)	0	346,411 (80.30%)
	1-3	55,320 (12.82 %)
	4-6	18,691(4.33%)
	6+	10,991(2.55%)
Number of outpatient visits in LHS	0	142,300(32.98%)
ambulatory care /Year (N)	1-30	287,962(66.75%)
	Above30+	1,151(0.27%)
Number of Hospitalizations/Year (N)	0	417,825(96.85%)
	1	11,545(2.68%)
	2	1,549(0.36%)
	3+	494(0.11%)
Number of ED admissions/Year (N)	0	385,109(89.27%)
	1-2	43,475(10.08%)
	3-4	2,458(0.57%)
	5+	371(0.09%)
Mean last HgbA1c level (%)		6.5±1.2
HgbA1c level categories	No test	377,837(87.58%)
	<5.7	20,238(4.69%)
	5.7-6.4	18,407(4.27%)
	6.5-7.9	10,084(2.34%)
	≥8.0	4,847(1.12%)
Mean last Hemoglobin level (g/dL)		12.9± 2.4
Hemoglobin level categories	No test	67,837(13.9%)
	<12 g/dL	98,569(20.2%)
	12+	322119(65.9%)
Mean last Creatinine level (mg/dL)		1.1±0.6
Creatinine level categories	No test	108,656(25.2%)
	<1.5	309458(71.7%)
	1.5+	13,299(3.1%)
Mean costs per patient NIS/Year (2011)		
Mean costs per patient NIS/ (2012-2016)		15,162± 25,242

Table 2: Distributions of total future medical costs

Variable		Mean total costs per patient NIS (2012-2016)
Age categories	≤30	2132.37 ± 1307.56
	31-60	4442.39 ± 2089.73
	61+	15757.44 ± 4113.1
Number of Chronic Medications (N)	0	3280.535±164.22
	1-3	10591.11±345.77
	4-6	20818.11± 4641.99
	6+	36311.93± 6194.6
Number of outpatient visits in LHS	0	1654.91±1308.23
ambulatory care /Year (N)	1-30	7801.157±2822.03
	Above30+	24846.91±4984.58
Number of Hospitalizations/Year (N)	0	5273.59 ± 2263.19
	1	19844.25± 4983.66
	2	33852.15±7267.28
	3+	51725.59±10138.6
Number of ED admissions/Year (N)	0	5310.188 ± 23536.83
	1-2	9856.694 ± 31296.62
	3-4	12238.45± 32466.32
	5+	18669.32 ± 53509.71
Last HgbA1c level categories	No Test	4355.496 ± 20731.2
	<5.7	9993.659 ± 32218.04
	5.7-6.4	14384.6 ± 38306.14
	6.5-7.9	22676.88 ± 48046.23
	≥8.0	34899.74 ± 59904.72

Table 3: Linear correlation (Spearman) between study variables and future medical cost

Variables	r	P
Mean Age(years)	0.291	<0.001
Male Gender	0.005	0.672
Mean number of Chronic Medications (N)	0.3011	0.048
Mean number of outpatient visits/Year (N)	0. 259	0.036
Mean number of Hospitalizations /Year (N)	0.1614	0.041
Mean number of Hospital Days /Year (N)	0.1495	0.046
Mean number of ED admissions/Year (N)	0.1214	0.034
Mean last HgbA1c level (%)	0.1943	0.028
Mean last Hemoglobin level (g/dL)	0.01	0.321
Mean last Creatinine level (mg/dL)	0.102	0.058

Table 4: Baseline model for future medical cost prediction

Variables	Coefficient	Standard Err.	95% CI	P-value
Mean number of ED admissions/Year (N)	958.58	61.83	837.41-1079.76	<0.001
Mean number of outpatient visits/Year (N)	211.69	4.39	203.08-220.30	<0.001
Mean number of Hospitalizations /Year (N)	6,720.33	126.30	6472.79-6967.88	<0.001
Mean number of Chronic Medications (N)	2,461.32	18.41	2425.23-2497.41	<0.001
Mean last HgbA1c level (%)	496.86	14.94	467.58-526.13	< 0.001
Intercept Cons.	1,655.05	33.95	1588.50-1721.59	<0.001

Table 5: Model for future medical cost prediction using dummy variables

Variables	Coefficient	Standard Err.	95% CI	P-value
Dummy Yes/No ED admissions/Year	411.66	122.37	171.83-651.51	<0.001
Dummy- more than one ED admissions/Year	878.37	182.64	520.39-1236.34	<0.001
Number of outpatient visits(0-30)/Year	225.08	4.85	215.08-234.64	<0.001
Number of outpatient visits(30-50)/Year	243.65	24.77	195.10-292.21	< 0.001
Dummy- one Hospitalization /Year	6,567.61	126.30	6235.89-6899.33	< 0.001
Dummy- two Hospitalizations /Year	13,913.11	439.67	13051-14774.85	< 0.001
Dummy- three and more Hospitalizations/Year	18,454.33	931.79	16628.03-	< 0.001
			20280.62	
Number of Chronic Medications	2,361.32	19.41	2324.49-2399.41	< 0.001
Dummy- HgbA1c No/Yes (less than 5.5%)	323.86	114.69	99.07-548.66	< 0.001
Dummy- HgbA1c Yes (5.5%-7.9%)	2,542.93	119.66	2308.39-2777.46	<0.001
Dummy- HgbA1c Yes (8% and more)	3,866.61	172.55	3528.41-4204.81	<0.001
Intercept Cons.	1,688.04	34.88	1619.67-1756.41	<0.001

Table 6: Baseline predictive cost model using "penalty" dummy variables

Variables	Coefficient	Standard Err.	95% CI	P-value
Dummy- Yes/No ED admissions/Year	417.66	122.34	177.83-657.07	<0.001
Dummy- more than one ED admissions/Year	831.77	183.54	473.39-1196.34	< 0.001
Dummy- ED admissions & Uncontrolled DM	2,376.86	650.18	1102.53-3651.07	< 0.001
Number of outpatient visits(0-30)/ Year	226.34	4.88	216.88-236.64	< 0.001
Number of outpatient visits(30-50)/ Year	231.65	24.79	183.14-280.42	<0.001
Dummy- one Hospitalization /Year	6,176.93	171.73	5840.89-6513.53	<0.001
Dummy- two Hospitalizations /Year	13,349.84	441.67	12484-14284.85	<0.001
Dummy- three and more Hospitalizations/Year	17,729.33	933.45	15618.03-	<0.001
			19807.62	
Dummy- Hospitalizations & Uncontrolled DM	10,224.45	789.37	8677.31-11771.6	<0.001
Number of Chronic Medications	2,372.26	19.43	2334.49-2410.41	<0.001
Dummy- No Chronic Medications & Uncontrolled	1,064.31	519.85	45.41-2083.21	0.041
DM				
Dummy- HgbA1c No/Yes (less than 5.5%)	433.18	115.16	207.07-658.66	<0.001
Dummy- HgbA1c Yes (5.5%-7.9%)	2,234.33	125.66	1988.61-2479.86	<0.001
Dummy- HgbA1c Yes (8% and more)	3,168.99	190.81	2794.95-3542.81	<0.001
Intercept Cons.	1,693.31	34.88	1624.93-1761.69	<0.001
1	1	1		1

References 271 1. Dattalo M, Nothelle S, Chapman EN, Targeting enhanced services toward high-cost, high-272 need medicare patients. New Directions in Geriatric Medicine: Concepts, Trends, and 273 Evidence-Based Practice (pp. 13-30). Springer International Publishing, (2016). 274 https://doi.org/10.1007/978-3-319-28137-7 2 275 2. Central Bureau of Statistics. State of Israel National Expenditure on Health 1962-2019. 276 Publication No. 1735, Retrieved from 277 https://www.cbs.gov.il/he/publications/Pages/2020/%D7%94%D7%94%D7%95%D7%A6% 278 D7%90% D7%94-% D7%94% D7%9C% D7%90% D7%95% D7%9E% D7%99% D7%AA-D7%90% D7%94-% D7%94% D7%90% D7%95% D7%95% D7%95% D7%99% D7%95% D7%95%279 %D7%9C%D7%91%D7%A8%D7%99%D7%90%D7%95%D7%AA-2019-1962.aspx 280 3. Zulman DM, Pal Chee C, Wagner TH, et al. Multimorbidity and healthcare utilization 281 among high-cost patients in the US Veterans Affairs Health Care System. BMJ Open 282 2015;**5**:e007771. 283 4. Effective Care for High-Need Patients: Opportunities for Improving Outcomes, Value and 284 Health, National Academy of Medicine, July 6, 2017. Retrieved from 285 https://nam.edu/initiatives/clinician-resilience-and-well-being/effective-care-for-high-need-286 patients/ 287 5. Hayes SL, Salzberg CA, McCarthy D, Radley DC, Abrams MK, Shah T, Anderson GF 288 High-need, high-cost patients: Who are they and how do they use health care—A 289 population-based comparison of demographics, health care use, and expenditures. New 290 York, NY: The Commonwealth Fund, 2016. Retrieved from 291 http://www.commonwealthfund.org/publications/issue-briefs/2016/aug/high-need-high-292 costpatients-meps1 293 6. Powers BW, et al. Impact of complex care management on spending and utilization for high-294 need, high-cost Medicaid patients. Am J Manag Care. 2020. PMID: 32059101 295 https://pubmed.ncbi.nlm.nih.gov/32059101/ 296 7. Charlson ME, Pompei P, Ales KL, MacKenzie CR, A new method of classifying prognostic 297 comorbidity in longitudinal studies: development and validation. J Chronic Dis. 298 1987;40(5):373-8 299 8. Charlson ME, Charlson RE, Peterson JC, Marinopoulos SS, Briggs WM, Hollenberg JP. The 300 Charlson comorbidity index is adapted to predict costs of chronic disease in primary care 301 patients. J Clin Epidemiol. 2008 Dec; 61(12):1234-40. Epub 2008 Jul 10. 302 9. van Walraven C, Dhalla IA, Bell C, Etchells E, Stiell IG, Zarnke K, et al. Derivation and 303 validation of an index to predict early death or unplanned readmission after discharge from 304 hospital to the community. CMAJ. 2010;182(6):551–7. 305 10. Farley JF, Harley CR, Devine JW, A comparison of comorbidity measurements to predict 306 healthcare expenditures, Am J Manag Care. 2006;12(2):110-9 307 11. Gulley SP, Rasch EK, Chan L. The complex web of health: relationships among chronic 308 conditions, disability, and health services, Public Health Rep. 2011;126(4):495-507 309 12. Reichard A, Gulley SP, Rasch EK, Chan L, Diagnosis isn't enough: Understanding the 310 connections between high health care utilization, chronic conditions and disabilities among 311 U.S. working age adults, Disabil Health J. 2015;8(4):535-46. 312 13. Schoen C, Osborn R, Squires D, Doty M, Pierson R, Applebaum S. New 2011 survey of 313 patients with complex care needs in eleven countries finds that care is often poorly 314 coordinated. Health Aff (Millwood). 2011; 30(12):2437-48. Epub 2011 Nov 9. 315 14. Rudin RS, Gidengil CA, Predmore Z, Schneider EC, Sorace J, Hornstein R, Identifying and 316 Coordinating Care for Complex Patients: Findings from the Leading Edge of Analytics and 317

Health Information Technology, Santa Monica, CA: RAND Corporation, 2016. 318 https://www.rand.org/pubs/research_reports/RR1234.html. 319 15. Peacock S, Chan C, Mangolini M, Johansen D, Techniques for Measuring Efficiency in 320 Health Services, Productivity Commission Staff Working Paper, July 2001 321 https://www.pc.gov.au/research/supporting/measuring-health-services/tmeihs.pdf 322 16. Hazel-Fernandez L, Li Y, Nero D, Moretz C, Slabaugh L, Meah Y, Baltz J, Patel NC, 323 Bouchard JR, Relationship of diabetes complications severity to healthcare utilization and 324 costs among Medicare Advantage beneficiaries, Am J Manag Care. 2015 Jan 1;21(1):e62-325 70. 326 17. Division for supervision of HMO's and additional health services in the Ministry of Health. 327 A Summary Report of the HMO's activities for 2017. Retrieved from: 328 https://www.health.gov.il/publicationsfiles/dochhashvaatui2017.pdf [Hebrew] 329 18. Hong CS, Siegel AL, Ferris TG, Caring for high-need, high-cost patients: what makes for a 330 successful care management program? New York: The Commonwealth Fund, August 2014 331 19. Intensive Outpatient Care Program (IOCP), Pacific Business Group on Health, California 332 Quality Collaborative, revised Dec 2016. 333 http://www.calquality.org/storage/documents/IOCPPCC Toolkit V7 112216.pdf 334 20. The Compass, How to Develop Indicators, retrieved from-335 https://www.thecompassforsbc.org/how-to-guides/how-develop-indicators 336 21. American Diabetes Association, Glycemic Targets: Standards of Medical Care in Diabetes – 337 2019, Diabetes Care 2019 Jan; 42(Supplement 1): S61-S70. https://doi.org/10.2337/dc19-338 S006 339 22. The Commonwealth Fund International Experts Working Group on Patients with Complex 340 Needs, Designing a High-Performing Health Care System for Patients with Complex Needs – 341 Ten Recommendations for Policymakers, Sep 2017. Retrieved from -342

https://www.commonwealthfund.org/sites/default/files/documents/ media files publicatio 343 ns fund report 2017 aug roland 10 recommendations for complex patients revisedexpa 344 nded.pdf 345 23. Hong C, Hwang A, Ferris T, Finding a Match: How successful Complex Care Programs 346 Identify Patients, California HealthCare Foundation, March 2015 347 https://www.chcf.org/wp-content/uploads/2017/12/PDF-FindingMatchComplexCare.pdf 348 24. Lu J, Britton E, Ferrance J, Rice E, Kuzel A, Dow A, *Identifying Future High Cost* 349 Individuals within an Intermediate Cost Population. Qual Prim Care. 2015;23(6):318-326. 350 25. Forrest CB, Lemke KW, Bodycombe DP, Weiner JP, Medication, Diagnostic, and Cost 351 Information as Predictors of High-Risk Patients in Need of Care Management, Am J Manag 352 Care. 2009 Jan;15(1):41-8. 353 26. Cumming RB, Knutsin D, Cameron BA, Derrick B. A comparative analysis of claims-based 354 methods of health risk assessment for commercial populations. Society of Actuaries. May 24, 355 2002. Available at: http://www.soa.org/ccm/content/areas-of-practice/special-interest-356 sections/health/health-section-sponsored-research. Accessed August 18, 2005. 357 27. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy 358 data. J Clin Epidemiol. 1992;45:197-203 359 28. Fishman PA, Goodman MJ, Hornbrook MC, et al. Risk adjustment using automated 360 ambulatory pharmacy data: the RxRisk Model. Med Care. 2003;41:84-99 361 29. Powers CA, Meyer CM, Cooper D, et al. Predicting one and two-year risk of hospitalization 362 using Patient Health Dimensions, a pharmacy-based risk index (abstract for material 363 presented at the 16th Annual Meeting of the Academy of Managed Care Pharmacy). J 364 Manage Care Pharmacy. 2004;10:200. 365 30. Zhao Y, Ellis RP, Ash AS, et al. Measuring population health risks using inpatient diagnosis 366 and outpatient pharmacy data. Health Serv Res. 2001;36:180-193. 367

31. Veazie PJ, Manning WG, Kane RL. *Improving risk adjustment for Medicare capitated*368

reimbursement using nonlinear models. Med Care. 2003;41:741-752
369

32. Chechulin Y, Nazerian A, Rais S, Malikov K. Predicting patients with high risk of becoming high-cost healthcare users in Ontario (Canada). Healthc Policy. 2014;9(3):68-79.
371
372

373